Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase I Dose-escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of Pegylated Arginine Deiminase Dimer (PA5) Injection in Patients With Advanced Solid Tumors

NCT07702162 is registered in ClinicalTrials.gov with Chongqing Peg-Bio Biopharm Co., Ltd. as lead sponsor.

NCT NCT07702162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07702162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase I Dose-escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of Pegylated Arginine Deiminase Dimer (PA5) Injection in Patients With Advanced Solid Tumors
Lead sponsor
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
November 14, 2025
Completion date
June 4, 2027
Enrollment
49 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, cancer